Compare Becton Dickinson and Co (BDX) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs KeyCorp — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while KeyCorp trades at $23.23 (market cap $25.15B). The key difference: Becton Dickinson and Co is the larger of the two by market cap, and KeyCorp pays the higher dividend (3.52%). Which is the better fit depends on your goals.
| BDX | KEY | |
|---|---|---|
Market Cap | $41.51B | $25.15B |
Sector | Health | Financials |
52-Week High | $185.39 | $23.43 |
52-Week Low | $135.49 | $16.78 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
KeyCorp (KEY) trades at $23.22, down 0.34% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamental recovery with Q1 2026 EPS beating expectations at $0.44 and a net income margin of 26.05% for 2025. Analyst consensus is heavily bullish with a $29.32 price target, and recent news highlights partnerships and a new $3 billion buyback program.
The outlook for KEY is positive, driven by earnings beats, robust capital returns, and improving profitability. Risks include volatile cash flows and macroeconomic sensitivity, but institutional support and a low P/E of 14.25 suggest undervaluation, offering potential upside for investors seeking regional bank exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
